A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies

Wei Jan Huang, Yen An Tang, Mei Yu Chen, Ying Jan Wang, Fu Han Hu, Tseng Wei Wang, Shi Wei Chao, Hui Wen Chiu, Ya Ling Yeh, Hsin Yi Chang, Hsueh Fen Juan, Pinpin Lin, Yi Ching Wang

Research output: Contribution to journalArticle

16 Citations (Scopus)


Many histone deacetylase (HDAC) inhibitors show limited therapeutic effects for solid tumors. Here, we develop a novel HDAC inhibitor YCW1 and verify the combination effect of YCW1 and cisplatin in lung cancer pre-clinical models. YCW1 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. YCW1 and cisplatin showed synergistic anti-tumor effects through impairment of DNA damage repair. YCW1 inhibited tumor growth in lung orthotopic and subcutaneously implanted xenograft models. YCW1 significantly suppressed lung metastases via inhibition of focal adhesion complex. Our findings suggested that YCW1 is a potential HDAC inhibitor for lung cancer treatment as single and in combination regimens with cisplatin.

Original languageEnglish
Pages (from-to)84-93
Number of pages10
JournalCancer Letters
Issue number1
Publication statusPublished - Apr 28 2014



  • Apoptosis
  • Cisplatin
  • Histone deacetylase inhibitor
  • Metastasis
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this